| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO And President | Director | CEO And President
3 companies
Szela Mary T serves as a CEO And President at TLSI and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 10 buys and 3 sells. Those positions are worth an estimated $5.0M at current prices.
Historically, Szela Mary T's trades have earned a below-average insider score of 47/100 across 7 rated trades. Over a 12-month horizon, 14.3% of those trades were profitable, with an average 12-month return of -3.4%.
The biggest single holding is TLSI (~$4.7M) as CEO And President. Net of sales, the recent Form 4 record there shows accumulation of 58,777 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | ABSI Absci Corporation | Director | Buy | 12,900 | $11.54 | $148,866.00 | +153.6% | - | - | |
| May 15, 2026 | TLSI Trisalus Life Sciences, Inc. | CEO And President | Buy | 39,682 | $2.59 | $102,776.38 | +3.9% | - | - | |
| Mar 17, 2026 | TLSI Trisalus Life Sciences, Inc. | CEO And President | Sell | 20,302 | $3.91 | $79,382.94 | -2.6% | - | - | |
| Jan 30, 2025 | TLSI Trisalus Life Sciences, Inc. | CEO And President | Buy | 10,040 | $5.15 | $51,753.70 | +2.3% | +0.4% | -2.7% | |
| Jan 28, 2025 | TLSI Trisalus Life Sciences, Inc. | CEO And President | Buy | 9,542 | $5.27 | $50,302.84 | +2.2% | +15.1% | -0.4% | |
| Sep 13, 2024 | TLSI Trisalus Life Sciences, Inc. | CEO And President | Buy | 14,815 | $5.09 | $75,358.85 | +4.0% | -12.2% | -2.0% | |
| Sep 10, 2024 | TLSI Trisalus Life Sciences, Inc. | CEO And President | Buy | 5,000 | $4.97 | $24,850.00 | +1.4% | -16.2% | -5.2% | |
| Jun 22, 2020 | CHRS Coherus Oncology, Inc. | Director | Sale+OE | 54,997 | $17.58 | $966,759.26 | -100% | - | - |